文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

乳酸林格液与生理盐水用于脓毒症诱导性低血压初始液体复苏的比较

Lactated Ringer's or Normal Saline for Initial Fluid Resuscitation in Sepsis-Induced Hypotension.
PubMed 文献 · Crit Care Med · 2025-02-19
一句话结论在脓毒症诱导性低血压患者中,初始复苏主要使用乳酸林格液(≥95%的复苏前液体)与较低的90天院内死亡风险相关(校正HR 0.71),并增加28天无住院天数。

该研究为CLOVERS随机对照试验的二次分析,纳入美国60个中心ICU和急诊科2018年3月至2022年1月收治的1563例脓毒症诱导性低血压成人患者,根据随机化前初始液体复苏主要使用的液体类型(≥95%为同一液体)分为乳酸林格液组(622例,39.8%)和0.9%盐水组(690例,44.1%)。乳酸林格液组90天出院前死亡76/622例(12.2%),0.9%盐水组110/690例(15.9%),校正HR 0.71(95%CI 0.51-0.99;p=0.043)。乳酸林格液组28天无住院天数多于0.9%盐水组(16.6±10.8天 vs 15.4±11.4天;校正均数差1.6天[95%CI 0.4-2.8天;p=0.009])。0.9%盐水治疗与较高的血清氯水平和较低的血清碳酸氢盐水平相关。作者认为,与0.9%盐水相比,乳酸林格液初始液体复苏可能与脓毒症诱导性低血压患者生存改善相关。

要点

  • 在脓毒症诱导性低血压患者中,初始复苏主要使用乳酸林格液(≥95%复苏前液体)与90天出院前死亡风险降低相关:校正HR 0.71(95%CI 0.51-0.99;p=0.043)。
  • 乳酸林格液组90天出院前死亡76/622例(12.2%),0.9%盐水组110/690例(15.9%)。
  • 乳酸林格液组28天无住院天数多于0.9%盐水组:16.6±10.8天 vs 15.4±11.4天,校正均数差1.6天(95%CI 0.4-2.8天;p=0.009)。
  • 0.9%盐水治疗与较高的血清氯水平和较低的血清碳酸氢盐水平相关。
  • 作者认为,与0.9%盐水相比,乳酸林格液初始液体复苏可能与脓毒症诱导性低血压患者生存改善相关。

适用人群与场景

  • CLOVERS试验纳入的成人患者,疑似或确诊感染且由脓毒症引起的低血压。
  • 场景为美国60个中心的ICU和急诊科,时间范围为2018年3月至2022年1月。
  • 本分析仅纳入随机化前初始液体复苏主要使用乳酸林格液或0.9%盐水(即≥95%的复苏前液体为同一液体)的患者。

诊断标准与关键阈值

  • 分组标准:根据随机化前初始液体复苏主要使用的液体类型分组,即≥95%的复苏前液体为乳酸林格液或0.9%盐水。

处置流程与药物剂量

  • 参与者在随机化前接受1-3 L晶体液进行初始液体复苏。
  • 本分析按随机化前初始液体复苏主要使用的液体类型(≥95%的复苏前液体)将患者分为乳酸林格液组和0.9%盐水组。

研究设计与关键结果

  • 研究类型:随机对照CLOVERS试验的二次分析;样本量1563例脓毒症诱导性低血压患者,其中622例(39.8%)接受乳酸林格液,690例(44.1%)接受0.9%盐水作为初始液体复苏。
  • 主要终点:90天出院前死亡在乳酸林格液组为76/622例(12.2%),在0.9%盐水组为110/690例(15.9%),校正HR 0.71(95%CI 0.51-0.99;p=0.043)。
  • 关键次要终点:28天无住院天数乳酸林格液组为16.6±10.8天,0.9%盐水组为15.4±11.4天,校正均数差1.6天(95%CI 0.4-2.8天;p=0.009)。
  • 0.9%盐水治疗与较高的血清氯水平和较低的血清碳酸氢盐水平相关。

证据类型、等级与局限

  • 证据类型:随机对照试验(CLOVERS)的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,与0.9%盐水相比,乳酸林格液初始液体复苏可能与脓毒症诱导性低血压患者生存改善相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To assess whether initial fluid resuscitation with lactated Ringer's solution compared with 0.9% saline is associated with improved clinical outcomes in patients with sepsis-induced hypotension.

DESIGN: Secondary analysis of the randomized controlled Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis (CLOVERS) trial.

SETTING: ICUs and emergency departments in 60 U.S. centers from March 2018 to January 2022.

PATIENTS: Participants from the CLOVERS trial. Adult patients with a suspected or confirmed infection and hypotension caused by sepsis.

INTERVENTIONS: Participants received 1-3 L of crystalloid fluid for initial fluid resuscitation before randomization. In this analysis, participants were categorized into a lactated Ringer's group and a 0.9% saline group based on the fluid type predominantly used for the initial fluid resuscitation (i.e., ≥ 95% of pre-randomization fluid).

MEASUREMENTS AND MAIN RESULTS: Of 1563 participants with sepsis-induced hypotension included in the CLOVERS trial, 622 (39.8%) received lactated Ringer's solution and 690 (44.1%) received 0.9% saline as solution for the initial fluid bolus. Death before discharge home by day 90 occurred in 76 of 622 participants (12.2%) in the lactated Ringer's group and in 110 of 690 participants (15.9%) in the 0.9% saline group, resulting in an adjusted hazard ratio of 0.71 (95% CI, 0.51-0.99; p = 0.043). Patients receiving lactated Ringer's solution had more hospital-free days at 28 days than those receiving 0.9% saline (16.6 ± 10.8 vs. 15.4 ± 11.4, respectively; adjusted mean difference, 1.6 d [95% CI, 0.4-2.8 d; p = 0.009]). Treatment with 0.9% saline was associated with higher levels of serum chloride and decreased levels of serum bicarbonate.

CONCLUSIONS: Initial fluid resuscitation with lactated Ringer's solution, compared with 0.9% saline, might be associated with improved survival in patients with sepsis-induced hypotension.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Gelbenegger G, Shapiro NI, Zeitlinger M, et al. Lactated Ringer's or Normal Saline for Initial Fluid Resuscitation in Sepsis-Induced Hypotension. Crit Care Med. 2025. PMID: 39969246. doi:10.1097/CCM.0000000000006601

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。